Study S001290

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05569772
Acronym: SERENA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: RECRUITING
Enrollment: 252
Start: 2023-09-14
Primary completion: 2030-03
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Conditions: Glucose Intolerance After a Recent History of Gestational Diabetes
Interventions: DRUG:Semaglutide Pen Injector; DRUG:Semaglutide placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:2022-502082-22-00

Registered primary outcomes

Development of T2DM [by 160 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015468	Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. Vanlaer Y, BMJ open	2026	Protocol	PMID 42493207 DOI	cites ClinicalTrials.gov:NCT05569772; cites CTIS:2022-502082-22-00; registry reference RESULT:42493207